Overview of Dr. Laccetti
I am a medical oncologist specializing in the management of prostate cancer and other malignancies of the genitourinary tract. My primary aim is to provide evidence-based, personalized patient care that balances aggressive treatment strategies and quality of life.
I have a strong foundation in clinical and outcomes research previously investigating strategies to improve access to oncology clinical trials and how cancer patients interface with electronic medical record portals. My current research aims to develop novel remote monitoring strategies for cancer patients utilizing emerging technologies including wearable activity trackers (such as Fitbit®) and smart-phone survey applications. Through development and implementation of these tools, I hope to achieve greater insight into the patient experience facilitating improvement of clinical trial design, patient safety, outcomes and treatment selection. I am also investigating the relationship between prostate cancer, metabolic syndrome and physical activity/exercise. I hope to develop prescriptive exercise interventions to improve prostate cancer outcomes and quality of life, while informing disease biology.
In my free time, I enjoy the running, hiking, ice hockey and spending time with my wife.
Office
353 East 68th Street
New York, NY 10065
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2012 - 2015
- Albany Medical CollegeClass of 2012
- Union CollegeB.S., Chemistry - Music, Suma Cum Laude
Certifications & Licensure
- NY State Medical License 2019 - 2026
- NJ State Medical License 2019 - 2025
- TX State Medical License 2014 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2024-10-18 - 2 citationsCabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2024-08-01 - 2 citationsA Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastati...Andrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, Wolfgang A Weber, Michael J Morris
Clinical Nuclear Medicine. 2023-11-01
Press Mentions
- Men Who Drink Milk at Higher Risk for Prostate CancerJune 11th, 2022
- Obesity in Men Linked to Increased Risk of Fatal Prostate CancerMay 6th, 2022
- Obesity Raises a Man's Odds for Fatal Prostate CancerMay 5th, 2022
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: